WallStreetZenWallStreetZen

NASDAQ: ASND
Ascendis Pharma A Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Ascendis Pharma A revenue was $418.98M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Mar 31, 2025 was $109.7M, down 39.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ASND annual revenue was $378.8M, with 27.8% growth year-over-year.

ASND past revenue growth

How has ASND's revenue growth performed historically?

Company
12.06%
Industry
1,361.15%
Market
34.96%
ASND's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ASND's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ASND's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ASND revenue history

Current Revenue
$400.8M
Current Earnings
-$371.4M
Current Profit Margin
-92.7%

Be the first to know when ASND announces revenue.

ASND Revenue History By Year

ASND Yearly RevenueASND RevenueASND ChangeASND Revenue Growth
2024-12-31$378.79M$82.44M+27.82%
2023-12-31$296.35M$241.91M+444.36%
2022-12-31$54.44M$45.60M+515.94%
2021-12-31$8.84M$359.37k+4.24%
2020-12-31$8.48M-$6.55M-43.58%
2019-12-31$15.03M$2.87M+23.57%
2018-12-31$12.16M$10.33M+562.16%
2017-12-31$1.84M-$3.01M-62.12%
2016-12-31$4.85M-$3.97M-44.99%
2015-12-31$8.81M-$8.11M-47.93%
2014-12-31$16.93M-$11.14M-39.69%
2013-12-31$28.07M$7.51M+36.55%
2012-12-31$20.56MN/AN/A

1 of 1

Ascendis Pharma A Revenue FAQ

What was ASND's revenue last quarter?

On Invalid Date, Ascendis Pharma A (NASDAQ: ASND) reported Q1 2025 revenue of $109.73 million up 5.28% year over year. In the same quarter last year, Ascendis Pharma A's revenue was $104.23 million.

What was Ascendis Pharma A's revenue in 2024?

Ascendis Pharma A's annual revenue for the twelve months ending Dec 31, 2024 was $378.79 million, a 27.82% increase year over year.

How much does Ascendis Pharma A make in a day?

Based on Ascendis Pharma A annual revenue for the past five years, ASND makes an average of $409,262.67 per day.

What was Ascendis Pharma A's annual revenue growth in the past year?

As of Q2 2025, Ascendis Pharma A's revenue has grown 12.06% year over year. This is 1,349.09 percentage points lower than the US Biotechnology industry revenue growth rate of 1,361.15%. Ascendis Pharma A's revenue in the past year totaled $418.98 million.

How much does Ascendis Pharma A make in a year?

Ascendis Pharma A's revenue by year for the past five years is:
  • Ascendis Pharma A's revenue for the twelve months ending Dec 31, 2024 was $378.79 million, a 27.82% increase year over year.
  • Ascendis Pharma A's annual revenue for Dec 31, 2023 was $296.35 million, a 444.36% increase from 2022.
  • Ascendis Pharma A's annual revenue for 2022 was $54.44 million, a 515.94% increase from 2021.
  • Ascendis Pharma A's annual revenue for 2021 was $8.84 million, a 4.24% increase from 2020.
  • Ascendis Pharma A's annual revenue for 2020 was $8.48 million, a 43.58% decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.